Drugs / AD182
last change Sep 2021 re-read 2 minutes ago

AD182

Developed for
obstructive sleep apnea syndrome
Investigated by
Apnimed

Trials 1 · a red edge is where a trial was stopped

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04645524 Dec 2020 → Sep 2021 obstructive sleep apnea syndrome Apnimed Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AD182 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04645524
Route Oral Oral capsule administered before bed” NCT04645524